ARA-290 Peptide – User Manual & Research Protocol Guide

ARA-290 (also known in research literature as a non-erythropoietic erythropoietin-derived peptide) is studied for its role in tissue protection, inflammatory modulation, and nerve repair signaling. In laboratory settings, it is investigated for cytoprotective pathways, small-fiber nerve models, and regenerative physiology research.

Research Applications

Tissue protection and cytoprotective signaling studies
Neuroregeneration and small-fiber nerve models
Inflammatory pathway modulation research
Pain signaling and repair physiology investigations
Microvascular and cellular recovery models

Disclaimer: ARA-290 is for research and experimental use only and is not FDA-approved for therapeutic use.

Lyophilized Powder

Freeze-dried ARA-290 intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used as an injectable research preparation after proper reconstitution.

ARA-290 is studied for its ability to:

• Activate tissue-protective receptor signaling pathways
• Modulate inflammatory cytokine responses
• Support cellular repair and regeneration mechanisms
• Promote nerve repair signaling in experimental models
• Provide cytoprotective effects independent of erythropoiesis

Observed effects are derived from preclinical and investigational research settings.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 2–4 mg per administration, generally once daily, often in cytoprotective research models.

Short-Course Research

Some studies use 2–4 mg daily in limited-duration research protocols.

Protocol-Based Study

Dosing and frequency may be protocol-dependent, determined by the specific research design and objectives.

Important

There is no approved human dosage. The ranges above reflect commonly cited research patterns only.

Initiation

A 1-week phase used for initial response observation at the start of the study.

Active Study Phase

Typically 2–6 weeks, focused on evaluating repair mechanisms and signaling pathways.

Rest Period

A 2–4 week interval between research cycles to allow recovery and system reset.

Note

Cycle duration may vary depending on the study design and research endpoints.

Supplies

Sterile bacteriostatic water
Sterile syringe
Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.
   Example: 4 mg vial + 1 mL → 4 mg/mL
3. Swirl gently to dissolve (do not shake).
4. Refrigerate at 2–8°C after reconstitution.
5. Use within 2–4 weeks or per protocol.

Maintain sterile techniqueRotate administration sites in injectable modelsDocument preparation concentration and dateFollow institutional research standards

Lyophilized Powder

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve product quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

Research use only
Not for therapeutic application
Human safety outside controlled research is not established
Potential research observations: injection-site irritation
Maintain sterile handling technique
Keep out of reach of unauthorized personnel

Peptide: ARA-290
Category: Neuroprotective & Regenerative Research
Delivery: Injectable research model
Typical Investigational Range: 2–4 mg per administration
Cycle: 2–6 week research protocols
Storage: Refrigerated after reconstitution